

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2022

**Anebulo Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-40388  
(Commission  
File Number)

85-1170950  
(IRS Employer  
Identification No.)

1415 Ranch Road 620 South, Suite 201  
Lakeway, Texas  
(Address of principal executive offices)

78734  
(Zip Code)

Registrant's telephone number, including area code: (512) 598-0931

N/A  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	ANEB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On October 28, 2022, Anebulo Pharmaceuticals, Inc. (the "Company") held its 2022 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the proposals listed below, each of which was described in the Company's proxy statement for the Annual Meeting. The voting results are set forth below.

**Proposal No. 1 - Election of Directors**

The stockholders elected the following three individuals to the Board of Directors to hold office until the 2025 Annual Meeting of Stockholders as Class II directors. There were no nominees other than those listed below. The voting results are as follows:

Name	Votes For	Withheld	Broker Non-Votes
Nat Calloway	15,985,642	7,456	0
Areta Kupchyk	15,982,304	10,794	0
Kenneth Lin	15,982,304	10,794	0

**Proposal No. 2 – Ratification of the selection by the Audit Committee of the Board of Directors of EisnerAmper LLP as the independent registered public accounting firm of the Company for its fiscal year ending June 30, 2023.**

The stockholders approved the ratification of the selection by the Audit Committee of the Board of Directors of EisnerAmper LLP as the independent registered public

accounting firm of the Company for its fiscal year ending June 30, 2023. The voting results are as follows:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
15,992,762	335	1	0

Brokers were entitled to cast votes on this proposal without voting instructions from the beneficial owners of the shares. As a result, there were no broker non votes with respect to this proposal.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 28, 2022

**ANEBULO PHARMACEUTICALS, INC.**

By: */s/ Rex Merchant*  
Rex Merchant  
Chief Financial Officer

---